N/A N=16 Endoscopic Peroral Myotomy for Treatment of Achalasia
Achalasia
Primary: Treatment Success Defined as Symptom Relief 3 Months After Treatment Based on an Eckhardt Score ≤ 3 — 1.4; 8.8 Eckardt Score — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
N/A N=40 Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?
Chest Pain Atypical Syndrome
Primary: Mean Change in Esophageal Length With Acid — -0.40; -0.39 centimeters
Phase 3 N=318 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
Eosinophilic Esophagitis (EoE)
Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001
N/A N=44 An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Gastroesophageal Reflux Disease
Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
Phase 3 N=80 Gastroesophageal Reflux Treatment in Scleroderma
Gastroesophageal Reflux Disease · Systemic Sclerosis · Scleroderma
Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)
Early Phase 1 N=30 Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)
Systemic Sclerosis
Primary: Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure)…
Phase 1 N=5 Topical Bethanechol for Improvement of Esophageal Dysmotility
Esophageal Dysmotility
Primary: Distal Contractile Integral — 178.3; 272.3; 261.8 mmHg*s*cm
N/A N=18 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Refractory Anastomotic Esophageal Strictures
Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159
N/A N=37 a/LCI-OCT Pilot in Esophagus
Barrett Esophagus
Primary: Percentage of Correctly Identified Positive (Dysplastic) Biopsies — 100.0 percentage of correct identifications
Phase 2 N=78 Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
N/A N=175 Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation
Primary: Incidence of Esophageal Injury as Assessed by Endoscopy — 1; 12; 4; 0 participants
Phase 2 N=45 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
Barretts Esophagus With Dysplasia
Primary: Percentage of Patients With Successful Eradication — 45.5; 38.1; 36.4; 19.04 percentage of participants
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
N/A N=127 Ablation of Intestinal Metaplasia Containing Dysplasia
Barrett Esophagus
Primary: The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month — 85; 81.5 percentage of participants
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
Phase 2 N=30 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Esophagitis
Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters